

## Advances in the biological responses to radiation-induced DNA damage: A selection of papers from the Joint 43rd European Radiation Research Society (ERRS) and 20th German Society for Biological Radiation Research (GBS) Annual Meetings

Guest Editors:

**Prof. Dr. George Iliakis**  
Georg.Iliakis@uk-essen.de

**Prof. Dr. Alexandros G. Georgakilas**  
alexg@mail.ntua.gr

**Prof. Dr. Michael Hausmann**  
hausmann@kip.uni-heidelberg.de

**Prof. Dr. Verena Jendrossek**  
verena.jendrossek@uni-due.de

**Dr. Lorenzo Manti**  
manti@na.infn.it

Deadline for manuscript  
submissions:

**closed (31 December 2017)**


### Message from the Guest Editors

Dear Colleagues

The Special Issue of *Cancers* will consist of selected papers from the “Joint 43<sup>rd</sup> European Radiation Research Society and 20<sup>th</sup> German Society for Biological Radiation Research Annual Meetings”, taking place in Essen, Germany, on 17–21 September 2017. This conference represents one of the major European events for the scientific community working on the biological effects of radiation exposures at the molecular, cellular and systemic levels. The meeting represents a unique opportunity for scientists from all over the world to gather and share their most recent results. Particular attention is devoted to translational aspects and novel strategies for clinical applications, together with a particular focus on fundamental mechanisms of radiation action. This Special Issue aims to serve as a state-of-the-art overview of recent progress in the field.

Prof. George Iliakis  
Dr. Alexandros Georgakilas  
Dr. Lorenzo Manti  
Prof. Michael Hausmann  
Prof. Verena Jendrossek  
*Guest Editors*





## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High visibility:** indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews, Scopus and other databases. Citations available in PubMed, full-text archived in PubMed Central.

**Rapid publication:** manuscripts are peer-reviewed and a first decision provided to authors approximately 16.9 days after submission; acceptance to publication is undertaken in 4.2 days (median values for papers published in this journal in the second half of 2018).

## Contact Us

---